

| Row No | REC no | IRAS No | Name of Trial | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure Of Trial |
|--------|------------|---------|--|-----------------------------------|---|---|---|--|--|---|--|-----------------------------|
| 1 | 16/NE/0384 | 209045 | PARADISE-MI | Number Agreed | 5 | 5 | Date Agreed | 13/03/2020 | 16 | 13/03/2020 | 16 | Recruitment Finished |
| 2 | 17/LO/0402 | 209419 | IMmotion010 | Number Agreed | 3 | 3 | Date Agreed | 12/11/2019 | 3 | 12/11/2019 | 3 | Recruitment Finished |
| 3 | 15/NE/0350 | 181479 | RESP 3213 (Lung Volume Reduction Coil) | Number Agreed | 15 | 15 | Date Agreed | 12/11/2019 | 16 | 12/11/2019 | 16 | Recruitment Finished |
| 4 | 17/WM/0308 | 226910 | ALPINE 2: AZLI for children with CF and PA lung infection | Number Agreed | 2 | 2 | Date Agreed | 09/04/2020 | 3 | 09/04/2020 | 3 | Recruitment Finished |
| 5 | 17/EM/0059 | 221778 | 1245.121 EMPEROR-Reduced Study | Number Agreed | 7 | 7 | Date Agreed | 30/08/2019 | 7 | 30/08/2019 | 7 | Recruitment Finished |
| 6 | 17/LO/0041 | 219676 | CardioMEMS HF System OUS Post Approval Study | Number Agreed | 10 | 10 | Date Agreed | 31/07/2019 | 16 | 31/07/2019 | 16 | Recruitment Finished |
| 7 | 17/EE/0177 | 220722 | BOSTON: Open-label Study of SVD versus VD in patients with RRMM | Number Agreed | 5 | 5 | Date Agreed | 12/11/2019 | 5 | 12/11/2019 | 5 | Recruitment Finished |
| 8 | 19/NI/0037 | 250757 | Protocol 16-021 ? Pediatric PK | Number Agreed | 1 | 1 | Date Agreed | 24/09/2019 | 1 | 24/09/2019 | 1 | Recruitment Finished |
| 9 | 18/EM/0326 | 252819 | Action of Tezepelumab on airway inflammation in moderate-severe asthma | Number Agreed | 8 | 8 | Date Agreed | 13/02/2020 | 10 | 13/02/2020 | 10 | Recruitment Finished |
| 10 | 18/EM/0336 | 251477 | CEPHEUS | Number Agreed | 3 | 3 | Date Agreed | 19/07/2019 | 3 | 19/07/2019 | 3 | Recruitment Finished |
| 11 | 19/LO/0855 | 260338 | NKTR-214 Phase II urothelial cancer with low PD-L1 expression Study | Number Agreed | 1 | 1 | Date Agreed | 25/05/2020 | 4 | 25/05/2020 | 4 | Recruitment Finished |
| 12 | 12/NW/0694 | 109044 | MCRN150 (A0221047) | Number Agreed | 2 | 2 | Date Agreed | 07/11/2019 | 0 | 07/11/2019 | 0 | Recruitment Finished |
| 13 | 16/NW/0041 | 197706 | CANC - 4492 - SOLAR-1 | Number Agreed | 8 | 8 | Date Agreed | 26/02/2020 | 2 | 26/02/2020 | 2 | Recruitment Finished |
| 14 | 16/EE/0196 | 201273 | CHIL 5025 A 24 Week Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapgliflozin | Number Agreed | 2 | 2 | Date Agreed | 24/09/2019 | 1 | 24/09/2019 | 1 | Recruitment Finished |
| 15 | 16/EE/0183 | 199109 | MUSC 3998 | Number Agreed | 1 | 1 | Date Agreed | 12/11/2019 | 0 | 12/11/2019 | 0 | Recruitment Finished |
| 16 | 17/NE/0092 | 220929 | B5091007 - C.Difficile infection-9002/0359-Pfizer | Number Agreed | 18 | 18 | Date Agreed | 12/11/2019 | 7 | 12/11/2019 | 7 | Recruitment Finished |
| 17 | 16/EE/0463 | 214371 | ComplEement-1 | Number Agreed | 5 | 5 | Date Agreed | 30/10/2019 | 2 | 30/10/2019 | 2 | Recruitment Finished |
| 18 | 16/NW/0620 | 206738 | Pro2tect-Correction | Number Agreed | 2 | 2 | Date Agreed | 12/11/2019 | 0 | 12/11/2019 | 0 | Recruitment Finished |
| 19 | 16/NW/0621 | 206740 | Pro2tect-Conversion | Number Agreed | 2 | 2 | Date Agreed | 30/08/2019 | 0 | 30/08/2019 | 0 | Recruitment Finished |
| 20 | 17/EM/0058 | 221776 | 1245.110 EMPEROR-Preserved Study | Number Agreed | 6 | 6 | Date Agreed | 12/12/2019 | 1 | 12/12/2019 | 1 | Recruitment Finished |
| 21 | 18/LO/0416 | 235395 | Evaluation of Avelumab combined with Talazoparib in solid tumours | Number Agreed | 5 | 5 | Date Agreed | 07/10/2019 | 3 | 07/10/2019 | 3 | Recruitment Finished |
| 22 | 17/NW/0546 | 228365 | C16029: Phase 2/3 Randomized, Open-Label Study in Multiple Myeloma | Number Agreed | 3 | 3 | Date Agreed | 11/09/2019 | 0 | 11/09/2019 | 0 | Recruitment Finished |

| Row No | REC no | IRAS No | Name of Trial | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure Of Trial |
|--------|------------|---------|--|-----------------------------------|---|---|---|--|--|---|--|-----------------------------|
| 23 | 17/LO/1672 | 209107 | MDS Clinical Utility Study OMS002-1 | Number Agreed | 100 | 100 | Date Agreed | 12/11/2019 | 68 | 12/11/2019 | 68 | Recruitment Finished |
| 24 | 18/YH/0055 | 241341 | Jazz JZP963-201 | Number Agreed | 3 | 3 | Date Agreed | 22/10/2019 | 1 | 22/10/2019 | 1 | Recruitment Finished |
| 25 | 18/WA/0262 | 245893 | CL140FSGS | Number Agreed | 1 | 1 | Date Agreed | 18/07/2019 | 0 | 18/07/2019 | 0 | Withdrawn By Sponsor |
| 26 | 18/EM/0217 | 244390 | ANTHEM | Number Agreed | 4 | 4 | Date Agreed | 05/11/2019 | 0 | 05/11/2019 | 0 | Recruitment Finished |
| 27 | 18/EE/0197 | 246434 | Phase 2 study of the Safety and Efficacy of ADCT-402 on DLBCL Patients | Number Agreed | 5 | 5 | Date Agreed | 28/08/2019 | 2 | 28/08/2019 | 2 | Recruitment Finished |
| 28 | 18/EE/0296 | 250366 | Comparison of AZD9977 with Spironolactone in Heart Failure | Number Agreed | 3 | 3 | Date Agreed | 16/03/2020 | 1 | 16/03/2020 | 1 | Recruitment Finished |
| 29 | 19/EE/0014 | 256539 | IXchange | Number Agreed | 2 | 2 | Date Agreed | 10/12/2019 | 0 | 10/12/2019 | 0 | Recruitment Finished |
| 30 | 19/EM/0101 | 260487 | SCENIC Trial | Number Agreed | 5 | 5 | Date Agreed | 01/05/2020 | 1 | 01/05/2020 | 1 | Recruitment Finished |
| 31 | 19/EE/0200 | 265253 | Investigating tirzepatide versus semaglutide in Type 2 Diabetes | Number Agreed | 8 | 8 | Date Agreed | 17/01/2020 | 1 | 17/01/2020 | 1 | Recruitment Finished |